TrialBMC cancer2024

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

Takaaki Tokito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.